As part of a program to identify new compounds that have activity against orthopoxviruses, a number of 4-thionucleosides were synthesized and evaluated for their efficacies against vaccinia and cowpox viruses. Seven compounds that were active at about 1 M against both viruses in human cells but that did not have significant toxicity were identified. The 5-iodo analog, 1-(2-deoxy-4-thio-␤-D-ribofuranosyl)-5-iodouracil (4-thioIDU), was selected as a representative molecule; and this compound also inhibited viral DNA synthesis at less than 1 M but only partially inhibited the replication of a recombinant vaccinia virus that lacked a thymidine kinase. This compound retained complete activity against cidofovir-and ST-246-resistant mutants. To determine if this analog had activity in an animal model, mice were infected intranasally with vaccinia or cowpox virus and treatment with 4-thioIDU was given intraperitoneally or orally twice daily at 50, 15, 5, or 1.5 mg/kg of body weight beginning at 24 to 120 h postinfection and was continued for 5 days. Almost complete protection (87%) was observed when treatment with 1.5 mg/kg was begun at 72 h postinfection, and significant protection (73%) was still obtained when treatment with 5 mg/kg was initiated at 96 h. Virus titers in the liver, spleen, and kidney were reduced by about 4 log 10 units and about 2 log 10 units in mice infected with vaccinia virus and cowpox virus, respectively. These results indicate that 4-thioIDU is a potent, nontoxic inhibitor of orthopoxvirus replication in cell culture and experimental animal infections and suggest that it may have potential for use in the treatment of orthopoxvirus infections in animals and humans.
The potential use of orthopoxviruses as weapons of bioterrorism and the fact that one member of this group, monkeypox virus, is indigenous in West and Central Africa and has also been introduced through zoonotic spread into the United States have prompted the search for effective and nontoxic antiviral agents for the treatment of orthopoxvirus infections in both animals and humans. Since there is perceived to be little financial reward for the development of a new agent for the treatment of these infections, initial investigations focused on the development of agents that were already approved for use for another indication, such as herpes, AIDS, or hepatitis. One of these agents, cidofovir (CDV), which is approved for use for the treatment of cytomegalovirus retinitis in human immunodeficiency virus-infected patients, is very active in tissue culture cells against all of the orthopoxviruses, including variola virus (2, 7, 8, 9, 13, 15) , and has been shown to be highly effective for the treatment of animals experimentally infected with vaccinia, cowpox, ectromelia, and monkeypox viruses (4, 5, 10, 19, 26, 27, 33, 34) . Although CDV is approved for use for the emergency treatment of smallpox and complications of vaccination under an experimental Investigational New Drug application, its lack of oral bioavailability somewhat limits its use in a large orthopoxvirus outbreak.
In order to obtain a compound that retains the activity of CDV but that can be administered orally, a series of analogs was synthesized by attaching a long-chain alkoxyalkanol to CDV. One of these compounds, hexadecyloxypropyl CDV (CMX001), was about 100-fold more active than CDV against vaccinia virus and cowpox virus (15, 16) . A similar level of enhanced activity of CMX001 against variola and monkeypox viruses has been reported (12, 15) . In mice infected with vaccinia, cowpox, or ectromelia virus, CMX001 given orally as either a single dose or multiple doses was at least as effective as CDV, if not more so, in preventing mortality and reducing viral replication in target organs (6, 21, 28) . This compound is currently in phase I/II clinical studies for the treatment of orthopoxvirus and herpesvirus infections.
A second compound that is also in phase I/II clinical studies is a low-molecular-weight compound, ST-246, which has potent activity in vitro against all of the orthopoxviruses against which it has been tested (11, 29, 40) and which has been reported to be highly effective when it is given orally in preventing mortality or disease in mice infected with vaccinia, cowpox, or ectromelia virus (29, 40) . The compound has a mechanism of action different from that of CDV, and its activity is restricted to poxviruses.
Numerous nucleoside analogs have been reported to be active against vaccinia virus (7) . We have evaluated most of the antiviral agents that have been licensed for other uses for their activities against orthopoxviruses (15) and found that CDV, idoxuridine (IDU), and trifluridine have significant activities in vitro without being overtly toxic. The fact that the mechanism of action of IDU against herpes simplex virus involves phosphorylation of the drug by the virus-encoded UL23 thymidine kinase (TK) was of special interest to us, as we have reported that this enzyme is involved in the selective activation of certain inhibitors of orthopoxvirus replication (23) (24) (25) . In previous studies by Secrist et al. (32) and Rahim and colleagues (31) , a series of 2Ј-deoxy-4Ј-thiopyrimidine nucleosides were synthesized, and a number of these analogs had significant activity predominantly against the alphaherpesviruses. We subsequently found that one of these analogs, 1-(2Ј-deoxy-4Ј-thio-␤-D-ribofuranosyl)-5-iodouracil (4Ј-thioIDU; compound 5 in Fig. 1 ), also has potent activity in vitro against vaccinia and cowpox viruses. Subsequently, we synthesized and evaluated 16 other analogs for their activities against orthopoxvirus infections.
The purpose of the studies reported in this communication was to synthesize and evaluate a number of compounds in this series for their activities against vaccinia and cowpox viruses in vitro, investigate their mechanisms of action, determine if they retain their activities against other drug-resistant mutants, and compare their activities against vaccinia and cowpox virus infections in mice to the activity of CDV. (compound 17) were prepared by the same methodology described by Secrist et al. (32) .
MATERIALS AND METHODS

Synthetic chemistry.
Viruses and cells. Human foreskin fibroblast (HFF) cells were prepared as primary cultures from freshly obtained newborn human foreskins. Culture medium for both cell lines was minimal essential medium (MEM) with Earle's salts containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, 20 U/ml of penicillin, and 25 g/ml of gentamicin.
Drug susceptibility assays for vaccinia virus strains and cowpox virus. Plaque reduction and cytopathic effect (CPE) assays were used to determine drug susceptibility, as described previously (14) . For the plaque reduction assays, HFF cells were seeded into six-well plates, and the plates were incubated at 37°C with 5% CO 2 and 90% humidity. Two days later, drug at twice the final desired concentration was serially diluted 1:5 in 2ϫ MEM with 10% FBS to provide six concentrations. Aspiration of the culture medium from triplicate wells for each drug concentration was followed by addition of 0.2 ml per well of diluted virus, which gave 20 to 30 plaques per well in MEM containing 10% FBS, or 0.2 ml medium for drug toxicity wells. The plates were incubated for 1 h to allow the virus to adsorb and were shaken every 15 min. An equal amount of 1% agarose was added to each drug dilution, and the mixture was added to each well in 2-ml volumes. Infected monolayers were incubated for 3 days, stained with a solution of neutral red in phosphate-buffered saline (PBS), and incubated for an additional 5 to 6 h. The stain was aspirated, the plaques were counted by using a stereomicroscope at ϫ10 magnification, and the 50% effective concentrations (EC 50 s) were calculated by standard methods.
Cowpox virus ␤-galactosidase assay. Dependence on the viral TK was assessed by previously published methods (23, 24) . Briefly, monolayers of HFF cells in 96-well plates were incubated at 37°C for 24 h in a humidified incubator. The experimental compounds were then diluted in the plates, and either TK ϩ or TK Ϫ strains of cowpox virus were added at a multiplicity of infection of 0.05 PFU/cell. At 48 h postinfection, the medium was removed and the ␤-galactosidase substrate chlorophenol red-␤-galactopyranoside was added at a final concentration of 50 g/ml in PBS. The conversion of the colorimetric substrate was determined by measuring the absorbance at 570 nm, and EC 50 s were calculated by standard methods (21) . The ratio of the EC 50 for TK Ϫ viruses and the EC 50 for TK ϩ viruses was calculated and used as a measure of TK dependence. DNA synthesis inhibition assays. Monolayers of HFF cells were infected with vaccinia virus at an multiplicity of infection of 3 PFU/cell. After 24 h, the cells were harvested and total DNA was purified with a Wizard DNA purification kit (Promega, Madison, WI). The genome copy number was determined by realtime PCR with primers 5Ј-CTG CTG TGT GTA TGA AAT GCT TTA AG-3Ј and 5Ј-TCT CGG TTT CCT CAC CCA AT-3Ј and the strain VVTK-specific probe 6-carboxyfluorescein-5Ј-AGG CTT CCT TTT CTA AAC-3Ј-6-carboxytetramethylrhodamine (Applied Biosystems, Foster City, CA).
Cytotoxicity assays. (i) Neutral red uptake assay in stationary cells. HFF cells were seeded into 96-well plates at a concentration of 2.5 ϫ 10 4 cells per well, and the plates were incubated for 24 h. The medium was aspirated; and 125 l of each drug concentration was added to designated wells in triplicate, while 100 l of MEM with 2% FBS was added to all other wells. Serial 1:5 dilutions were made with a Beckman BioMek liquid handling system, and the plates were incubated for 7 days in a CO 2 incubator at 37°C. Aspirations of the well contents were followed by the addition of 100 l/well of a solution of neutral red in PBS and incubation for 1 h. The cells were washed with PBS by using a Nunc plate washer, and 200 l/well of 50% ethanol containing 1% glacial acetic acid was added. The plates were placed on a rotary shaker for 15 min, and the optical densities at 540 nm were read on a Bio-Tek plate reader. The concentration of drug that reduced cell viability by 50% (CC 50 ) was then calculated.
(ii) Cell proliferation assay. Twenty-four hours prior to assay, HFF cells were seeded into six-well plates at a concentration of 2.5 ϫ 10 4 cells per well in MEM containing FBS. On the day of the assay, the compounds were diluted serially in medium at increments of 1:5, resulting in concentrations covering a range from 100 to 0.03 M. The medium from the wells was aspirated, and 2 ml of each drug concentration was added to duplicate wells. The cells were incubated in a CO 2 incubator at 37°C for 3 days. After incubation, the medium-drug solutions were removed, 1 ml of 0.25% trypsin-EDTA was added to each well, and the plates were incubated until the cells started to detach from the plate. Vigorous pipetting was used to obtain a homogeneous cell suspension, 0.2 ml of the mixture was PYRIMIDINE NUCLEOSIDE ACTIVITY AGAINST POXVIRUSES 573 added to 9.8 ml of Isoton III solution, and counts were obtained with a Coulter counter. The counts for each sample were obtained three times, and two replicate wells were used for each sample. The 50% inhibitory concentration (IC 50 ) was calculated by standard methods. Antiviral activity in mice. Female BALB/c mice (age, 3 weeks) were obtained from Charles River Laboratories, Raleigh, NC. The mice were housed in groups in microisolator cages and were utilized at a quantity of 15 mice per treatment group. They were obtained, housed, utilized, and euthanized according to the regulatory policies of USDA and AAALAC. All animal procedures were approved by the University of Alabama at Birmingham Institutional Animal Care and Use Committee prior to the initiation of the studies. Antiviral compounds. CDV (Vistide; Gilead Sciences, Foster City, CA) was diluted in sterile saline to yield the desired doses in a 0.1-ml volume. It was administered as a fine suspension intraperitoneally (i.p.) once daily for 5 days. 4Ј-ThioIDU was provided as a dry powder, dissolved in a constant amount of dimethyl sulfoxide (DMSO), and then suspended in 0.4% carboxymethyl cellulose (CMC) to yield the desired doses in a 0.1-ml volume for i.p. injection or a 0.2-ml volume for oral gavage. Each dose was administered twice daily for 5 days beginning at various times after viral inoculation. Uninfected mice served as toxicity controls and were treated similarly.
Experimental infections. Vaccinia virus strain WR and cowpox virus infections were initiated by intranasal inoculation of anesthetized (ketamine-xylazine) BALB/c mice with approximately 90% lethal doses, which corresponded to 4 ϫ 10 4 PFU and 1.6 ϫ 10 4 PFU for cowpox virus and vaccinia virus, respectively (25, 27) . The virus inoculum was instilled into both nostrils with a micropipette at a total volume of 40 l per animal. For the mortality experiments, the animals were checked at least once daily for 21 days. Pathogenesis studies were performed with both vaccinia virus and cowpox virus in order to determine the effect of 4Ј-thioIDU on viral replication in the target organs of the mice. Three mice each from the control and the treated groups were euthanized on day 1, 3, 5, 7, or 10 postinoculation for collection of the lung, liver, spleen, and kidney. Samples were pooled by tissue type, homogenized in a 10% (wt/vol) suspension, and frozen until they were assayed for virus. The virus titers were determined by cocultivation of homogenates on Vero cells, and plaques were enumerated after 5 days of incubation.
Statistical evaluations. Mortality rates were analyzed by Fisher's exact test, and the mean day of death was determined by the Mann-Whitney U rank-sum test. A P value of Յ0.05 was considered significant.
RESULTS
Compounds active against vaccinia and cowpox viruses.
Seventeen 4Ј-thiopyrimidine nucleosides were synthesized and were initially screened by CPE assays to determine the efficacies of the compounds against both vaccinia and cowpox viruses. Seven of the compounds found to be efficacious by the CPE assays were subject to confirmatory plaque reduction assays, and these results, along with cytotoxicity data, are presented in Table 1 . All seven of these compounds had activities against both vaccinia and cowpox viruses that ranged from being 20-to 1,400-fold greater than the activity of CDV. The activity of one compound selected from the series, 4Ј-thioIDU, was also tested against vaccinia virus WR, and its activities against the Copenhagen strain of vaccinia virus and cowpox virus were compared. Selectivity indices (CC 50 /EC 50 ) ranged from Ͼ200 to 2,000 for 4Ј-thioIDU; in contrast, the values for CDV were Ͼ9 to Ͼ32. All of the compounds exhibited minimal toxicity in stationary cells, as measured by the neutral red uptake assay, but cytotoxicity against proliferating cells was considerable ( Table 1 ). The remaining 10 compounds were inactive when they were tested at 100 M.
Activity against drug-resistant viruses. The antiviral activities of these compounds observed in vitro prompted additional studies of their activities against strains of vaccinia virus that were resistant to CDV or ST-246, and 4Ј-thioIDU was used as the representative compound from this series. This molecule retained its antiviral activity against a drug-resistant strain of CDV that contained mutations in the E9L DNA polymerase gene (3), as well as a strain resistant to ST-246 that contained mutations in the F13L gene (38) ( Table 2 ). These data indicate that the mechanism of action of this molecule is distinct from the mechanisms of action of CDV and ST-246 and suggest that the molecule might be useful for the treatment of drug-resistant virus infections. The susceptibility of a recombinant virus lacking the J2R gene encoding the viral TK was also evaluated, since 4Ј-thioIDU is a thymidine analog. This recombinant virus appeared to be comparatively resistant to both 4Ј-thioIDU and IDU, while it remained fully sensitive to CDV, which does not require phosphorylation by this viral enzyme. These results initially suggested that the mechanism of action of 4Ј-thioIDU may be similar to that of IDU and that the viral TK may contribute to the phosphorylation of the drug. Mechanism-of-action studies. Additional studies were conducted to investigate the effects of the drug on viral infection. Previous results from our laboratory showed that the activity of IDU against cowpox virus was dependent on the viral TK, suggesting that 4Ј-thioIDU might act by a similar mechanism (25) . These studies were repeated and IDU exhibited TK dependence, while CDV and ST-246 were equally effective against both strains of virus (Table 3 ). The antiviral activity of 4Ј-thioIDU also proved to be largely dependent on the viral TK, which is consistent with our hypothesized mechanism. Subsequent studies examined its effects on viral DNA synthesis and confirmed that it is a potent inhibitor of viral DNA synthesis (Table 3 ). When they are taken together, the results of these studies suggest that this compound is likely phosphorylated by the viral TK and that at least one of the phosphorylated metabolites affects the synthesis of viral DNA. Nevertheless, the TK-resistant mutants were still partially sensitive to the drug, raising the possibility that other viral or cellular enzymes may also contribute to the phosphorylation of the compound.
In vivo activity of 4-thioIDU. To determine if 4Ј-thioIDU was active in an animal model infection, mice were inoculated intranasally with either vaccinia or cowpox virus. 4Ј-ThioIDU given i.p. twice daily beginning at 24 h after viral inoculation was highly effective (P Ͻ 0.001) at reducing or eliminating mortality when it was used at a dose of 50, 15, or 5 mg/kg of body weight against vaccinia virus or 15, 5, or 1.5 mg/kg against cowpox virus. As a comparison, CDV was used as a positive control and was found to provide complete protection at a dose of 15 mg/kg (Table 4) . Since it would be highly desirable for a drug for use for the treatment of poxvirus infections to be active when it was given by the oral route, we next determined the activity of 4Ј-thioIDU when it was given orally. The drug was administered twice daily beginning at 1, 2, 3, or 4 days after viral inoculation at a concentration of 15, 5, or 1.5 mg/kg and was highly effective (P Յ 0.0001) in preventing mortality against cowpox virus infection when treatment was initiated at as late as 4 days after infection but was ineffective when treatment with 5 mg/kg was begun at 5 days after infection ( Table  5) . The positive control, CDV, at 15 mg/kg significantly reduced the rate of mortality against cowpox virus infection, even if the initiation of therapy was delayed until 8 days postinfection. In other experiments whose results are not presented here, 4Ј-thioIDU significantly reduced the rate of mortality when it was given orally at 0.3 or 1.0 mg/kg and when treatment was initiated at 24 h after cowpox virus infection.
To determine the effect of oral treatment with 4Ј-thioIDU compared with that of CDV on the replication of vaccinia or cowpox virus in the target organs of mice, animals were inoculated with virus and were treated orally with 15 mg of 4Ј-thioIDU per kg twice daily beginning at 24 h after infection; CDV was given at 15 mg/kg i.p. once daily. Both of the treatment regimens resulted in significant decreases in the rates of mortality of the control mice (data not shown). In mice infected with vaccinia virus, the virus titers in the liver, spleen, and kidney tissues of both 4Ј-thioIDU-and CDV-treated mice were reduced to undetectable levels, about a 5-log 10 -unit reduction, but there was only about a 1-log 10 -unit decrease in the virus titers in lung tissue (Fig. 2) . When mice were infected with cowpox virus, treatment with 4Ј-thioIDU resulted in a 2-log 10 -unit reduction in virus titers in the liver, spleen, and kidney tissues (data not shown).
DISCUSSION
In addition to the potential threat of the use of an orthopoxvirus, particularly variola virus, as a weapon of bioterror, it is important to emphasize that another member of this group of viruses, monkeypox virus, is endemic in central Africa and is responsible for sporadic outbreaks in the Democratic Republic of the Congo. The ease with which this virus can spread and cause outbreaks in other continents, including North America, a 4Ј-ThioIDU was suspended in 10% DMSO in 0.4% CMC and was given i.p. in 0.1-ml doses. CDV was prepared in sterile saline and was given i.p. in 0.1-ml doses. Animals were treated with 4Ј-thioIDU twice daily for 5 days or with CDV once daily beginning at 24 h after viral inoculation.
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on October 15, 2017 by guest http://aac.asm.org/ was recently demonstrated with the importation of infected animals. It is important, therefore, to regard these agents as potential sources of emerging infections and to continue the goal of developing chemotherapeutic agents effective against these viruses. Although CDV is approved for use for the treatment of smallpox and complications arising from vaccination under an emergency Investigational New Drug application, its lack of activity when it is administered orally and its dose-limiting toxicity would severely limit its use in a large-scale outbreak. To address the need for additional therapies for orthopoxvirus infections, two highly active compounds, CMX001 (a lipid conjugate of CDV) and ST-246 (a small molecule), have advanced through preclinical studies and are being evaluated for their pharmacokinetics and toxicities in clinical studies. Since neither of these compounds has been approved for use for the treatment of orthopoxvirus infections in animals or humans, there continues to be a need for the development of additional therapeutic agents for these infections. We have investigated a group of 4Ј-thionucleosides that were reported to have activity against herpes simplex virus, that are related to IDU, and that are likely phosphorylated by virus-encoded TK (30) . We were particularly interested in these compounds because of previous observations that IDU and trifluridine were also potent inhibitors of orthopoxvirus replication and that the viral TK phosphorylated these drugs (7, 15, (23) (24) (25) . While IDU has been tested in mice with vaccinia virus infections (20, 36) , the drug was considerably less active than 4Ј-thioIDU, as we observed in the present study. A total of 17 compounds were synthesized, and 7 of these had activities in vitro against vaccinia and cowpox viruses at concentrations of about 1 M. Substitution of the pyrimidine base at the 5 position, particularly by halogen, resulted in a high level of activity. One of the first active compounds evaluated in this group was the thymidine analog, 4Ј-thioIDU; and 4Ј-thioIDU was used for subsequent experiments, including mechanismof-action, resistance, and in vivo experiments. While it may not be the most active or the least toxic compound of the group, it has an excellent selectivity index and was not visibly toxic in animals when it was used at 100 times the therapeutic concentration. The in vitro studies indicated that this compound was 30 to 300 times more active against vaccinia and cowpox viruses than CDV, and neither 4Ј-thioIDU nor CDV was toxic in stationary human cells. It should be pointed out, however, that all of these compounds, including 4Ј-thioIDU, are considerably more toxic in dividing cells than in nondividing cells.
A major problem with the development of new antiviral agents has been the appearance of resistant mutants, and any new agent should have activity against isolates resistant to existing drugs. Since there has essentially never been a clinical study with an antiviral agent for a disease caused by orthopoxvirus, there is no information regarding the development of resistance to any of these compounds in humans, and no resistant isolates have been recovered in studies of animals treated with any of the agents described above. The development of mutants resistant to CDV and ST-246 in vitro have been reported, although inordinately long passage histories were required to generate resistance to CDV (3, 18, 35, 37, 40) . In the present study, we showed that 4Ј-thioIDU was effective against both CDV-and ST-246-resistant mutants, suggesting that its mechanism of action is distinct from the mechanisms of action of CDV and ST-246. This is important, since the activities of combinations of 4Ј-thioIDU with either of these drugs might be synergistic and the use of combinations of these drugs may reduce the possibility of the development of resistance (22) . We previously reported that CMX001 and ST-246 act synergistically both in vitro and in vivo (30) , and the results presented here suggest that 4Ј-thioIDU might be a good addition to combination therapies with either or both of these drugs. Further studies will be required to document whether synergistic interactions exist between 4Ј-thioIDU and CMX001 or ST-246, but the potentially different mechanism of action exhibited by 4Ј-thioIDU makes it a valuable addition to the current set of drugs under development.
While 4Ј-thioIDU was active against both CDV-and ST- a 4Ј-ThioIDU was suspended in vehicle (10% DMSO in 0.4% CMC) and given orally in 0.2-ml doses. CDV was prepared in sterile saline and was given i.p. in 0.1-ml doses. Animals were treated twice daily with vehicle or 4Ј-thioIDU for 5 days or were treated with CDV once daily beginning at 1, 2, 3, 4, or 5 days after viral inoculation.
b NS, not significant compared to the results for the placebo-treated control.
246-resistant mutants of vaccinia virus, it exhibited reduced efficacy against a TK Ϫ strain of vaccinia virus, which suggests that the viral TK is involved in activation of the drug. This is significant, because the selective phosphorylation of this compound by the viral enzyme should result in an increased specificity for infected cells and decreased toxicity. This mechanism of action is distinct from the mechanisms of action of CMX001 and ST-246 and suggests that 4Ј-thioIDU could be used with either or both of those drugs as part of a combination regimen. Nevertheless, the drug retained significant activity against the TK mutant, which suggests that an additional kinase may be capable of activating the drug or that the compound may be acting by other mechanisms to inhibit the replication of orthopoxviruses and perhaps herpesviruses as well. 4Ј-ThioIDU clearly inhibited the synthesis of the DNA of the WR strain of vaccinia virus at an EC 50 of 0.6 M (Table 3) , which is higher than the efficacy in plaque reduction assays with the same strain (EC 50 , 0.04 M; Table 2 ) but which is comparable to the efficacy in plaque reduction assays with the Copenhagen strain of the virus (EC 50 , 0.5 M; Table 1 ). The differences in EC 50 s for DNA synthesis and antiviral efficacy that were observed may simply reflect biological variation related to the multiplicity of infection or strain differences, but we cannot exclude the possibility that other targets may be affected by this compound. Additional experiments will be required to determine if 4Ј-thioIDU inhibits DNA synthesis directly or whether the inhibition of DNA synthesis is a consequence of other defects in the replication cycle.
One of the most rigorous and important determinants of the potential of a new antiviral drug to enter a development path is its ability to reduce virus replication in an experimental animal model of infection. For the initial in vivo evaluation of 4Ј-thioIDU, mice were inoculated intranasally with either vaccinia or cowpox virus and were treated i.p. with various concentrations of drug by using a standard treatment regimen beginning at 24 h after infection. The drug was highly effective in preventing mortality at concentrations as low as 1.5 mg of drug per kg, which prompted a second series of studies to determine its activity when it was given orally. Importantly, greater than 70% protection was observed even if treatment with concentrations as low as 5 mg per kg was initiated as late as 4 days after infection. These results are equivalent or even superior to those seen with CDV (4, 5, 26, 33, 34) , CMX001 (28) , and ST-246 (29, 40) . We have previously reported that CDV, CMX001, and ST-246 given parenterally or orally all markedly reduced vaccinia or cowpox virus replication in the liver, spleen, and kidney but resulted in only a small reduction in virus replication in the lung (26) (27) (28) (29) . This observation is consistent with those of other investigators who have used animal models of vaccinia and cowpox virus infection (4, 34) and also ectromelia virus infection of mice (21) . In contrast to these results are the results of treatment with CDV by the intranasal or aerosol route, in which a significant reduction in virus titers in lung tissue has been reported (5, 33) . It may be that the high virus titers obtained during vaccinia and cowpox virus infections are more amenable to inhibition by drug delivered directly to the lung than to inhibition of drug given parenterally or orally. Another possibility that may explain the lack of an effect of parenteral or oral delivery in the lung is that the drug does not get to the site of infection. However, in mice inoculated with murine cytomegalovirus, both CDV and CMX001 at concentrations similar to those used in the poxvirus models reduced the virus titers in the lung as well as all of the other target organs by 5 log 10 units (17) . 4Ј-ThioIDU is a nucleoside analog that has potent activity against vaccinia and cowpox virus infections in vitro and in vivo. Its activity compares very favorably with those reported for CDV, CMX001, and ST-246; and it is not toxic at therapeutic levels in animals. Its mechanism of action appears to involve its phosphorylation by orthopoxvirus TK, and it inhibits viral DNA synthesis. It is also active against mutants resistant to CDV and ST-246 and may be valuable as part of a combination therapy that includes those drugs. The compound also has activity against the alphaherpesviruses and should continue to be evaluated for a potential role in the treatment of orthopoxvirus and certain herpesvirus infections in humans.
